Optiver Holding’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$126M Buy
3,430,800
+444,000
+15% +$21M 0.04% 108
2025
Q4
$152M Buy
2,986,800
+318,800
+12% +$16.3M 0.06% 85
2025
Q3
$148M Buy
2,668,000
+1,979,900
+288% +$116M 0.06% 74
2025
Q2
$47.5M Sell
688,100
-131,400
-16% -$8.94M 0.02% 109
2025
Q1
$56.9M Sell
819,500
-21,400
-3% -$1.77M 0.03% 91
2024
Q4
$72.3M Buy
840,900
+348,800
+71% +$37.7M 0.04% 86
2024
Q3
$58.6M Sell
492,100
-231,700
-32% -$30.9M 0.03% 100
2024
Q2
$103M Sell
723,800
-653,400
-47% -$86.6M 0.06% 82
2024
Q1
$177M Buy
1,377,200
+1,168,800
+561% +$139M 0.1% 62
2023
Q4
$21.6M Sell
208,400
-350,100
-63% -$34.6M 0.01% 221
2023
Q3
$50.8M Sell
558,500
-336,500
-38% -$29.6M 0.03% 142
2023
Q2
$72.4M Buy
895,000
+350,600
+64% +$28.6M 0.05% 125
2023
Q1
$43.3M Buy
544,400
+417,200
+328% +$29.6M 0.03% 174
2022
Q4
$8.61M Sell
127,200
-28,000
-18% -$1.64M 0.01% 246
2022
Q3
$7.73M Sell
155,200
-31,800
-17% -$1.7M 0.01% 194
2022
Q2
$10.4M Buy
+187,000
New +$10.4M 0.01% 158

Other funds holding NVO

Optiver Holding's NVO Position: Q1 2026 in Review

Optiver Holding sold out of Novo Nordisk (NVO) in Q1 2026, closing a stake of 983,717 shares — an estimated $46.6M sold.

Optiver Holding first reported a position in NVO in Q3 2021 and held it in 14 quarters. The position peaked at $50.1M in Q4 2025. 1,272 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Optiver Holding reported no remaining Novo Nordisk position as of Q1 2026 after selling out during the quarter.
  • Optiver Holding sold 983,717 Novo Nordisk shares in Q1 2026, an estimated $46.6M.
  • Optiver Holding first reported a position in Novo Nordisk in Q3 2021 and held it in 14 quarters.
  • Optiver Holding's Novo Nordisk position peaked at $50.1M in Q4 2025.
  • 1,272 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Optiver Holding's 13F filing for Q1 2026, filed 15 May 2026.